GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heartware International Inc (NAS:HTWR) » Definitions » EBITDA

Heartware International (Heartware International) EBITDA : $-35.0 Mil (TTM As of Jun. 2016)


View and export this data going back to 2008. Start your Free Trial

What is Heartware International EBITDA?

Heartware International's EBITDA for the three months ended in Jun. 2016 was $-4.8 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Jun. 2016 was $-35.0 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

Heartware International's EBITDA per Share for the three months ended in Jun. 2016 was $-0.28. Its EBITDA per share for the trailing twelve months (TTM) ended in Jun. 2016 was $-2.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.


Heartware International EBITDA Historical Data

The historical data trend for Heartware International's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heartware International EBITDA Chart

Heartware International Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -41.79 -71.28 -39.57 2.73 -48.72

Heartware International Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.37 -23.84 5.13 -11.50 -4.83

Competitive Comparison of Heartware International's EBITDA

For the Medical Devices subindustry, Heartware International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heartware International's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Heartware International's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Heartware International's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Heartware International's EBITDA for the fiscal year that ended in Dec. 2015 is calculated as

Heartware International's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2015, Heartware International's EBITDA was $-48.7 Mil.

Heartware International's EBITDA for the quarter that ended in Jun. 2016 is calculated as

Heartware International's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Jun. 2016, Heartware International's EBITDA was $-4.8 Mil.

EBITDA for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Heartware International  (NAS:HTWR) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Heartware International EBITDA Related Terms

Thank you for viewing the detailed overview of Heartware International's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Heartware International (Heartware International) Business Description

Traded in Other Exchanges
N/A
Address
Heartware International Inc was incorporated in Delaware on July 29, 2008 and became the successor issuer to HeartWare Limited, an Australian corporation, on November 13, 2008, as a result of the Australian Court approved redomiciliation of HeartWare Limited from Australia to Delaware. HeartWare is a medical device company engaged in developing implantable blood pumps for the treatment of advanced heart failure. The Company operates one reportable segment which includes the design, manufacture and marketing of medical devices for the treatment of advanced heart failure. The HeartWare Ventricular Assist System, which includes a left ventricular assist device, or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients with advanced heart failure. Beyond the HeartWare System, the company is also evaluating its next device, the Miniaturized Ventricular Assist Device. The MVAD is based on the same technology platform as the HeartWare System but adopts an axial flow, rather than a centrifugal flow, configuration and is being developed in multiple configurations. The MVAD designs are currently at the preclinical stage and undergoing animal studies focused on minimally invasive implantation techniques and are each approximately one-third the size of the HVAD Pump. The Company's competitors in the implantable cardiac assist space include Thoratec Corporation, Jarvik Heart, Inc., MicroMed Cardiovascular, Berlin Heart GmbH, and Sunshine Heart, Inc. HEARTWARE, HVAD, MVAD, PAL, CIRCULITE, SYNERGY and various company logos are the trademarks of the Company, in the United States, Europe, Australia and other countries.
Executives
Larkin C Raymond Jr director C/O MALLINCKRODT INC, 7733 FORSYTH BLVD, ST LOUIS MO 63105
Stephen N. Oesterle director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Cynthia L Feldmann director 17 WINTHROP ROAD, WAYLAND MA 01778
Seth Loring Harrison director 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Timothy J Barberich director 40 ELM ST, CONCORD MA 01752
Douglas Evan Godshall director, officer: President & Chief Exec Officer SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Robert Bain Thomas director SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Denis Newell Wade director SUITE 4 LEVEL 46, 2 PARK STREET, SIDNEY C3 2000
Adage Capital Partners Gp, L.l.c. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Partners, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Advisors, L.l.c. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert Atchinson 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Phillip Gross 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
David Mcintyre officer: CFO & COO SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Muneer A Satter 10 percent owner C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611

Heartware International (Heartware International) Headlines

From GuruFocus

Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 3,415 Shares

By GuruFocus Research GuruFocus Editor 11-25-2009

Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 1,580 Shares

By GuruFocus Research GuruFocus Editor 12-04-2009

Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 2,857 Shares

By GuruFocus Research GuruFocus Editor 02-24-2011

Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 2,521 Shares

By GuruFocus Research GuruFocus Editor 12-08-2009

Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 3,400 Shares

By GuruFocus Research GuruFocus Editor 12-01-2009

Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 1,000 Shares

By GuruFocus Research GuruFocus Editor 11-19-2009

Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 4,967 Shares

By GuruFocus Research GuruFocus Editor 01-30-2010

Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 3,300 Shares

By GuruFocus Research GuruFocus Editor 02-27-2010

Heartware International Inc (HTWR) CFO & COO David Mcintyre sells 21,834 Shares

By GuruFocus Research GuruFocus Editor 04-30-2010

Baron Funds Comments on HeartWare International

By Holly LaFon 05-05-2014